Current status and progress in research on dressing management for diabetic foot ulcer

Frontiers in Endocrinology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 17, 2023

Diabetic foot ulcer (DFU) is a major complication of diabetes and associated with high risk lower limb amputation mortality. During their lifetime, 19%–34% patients can develop DFU. It estimated that 61% DFU become infected 15% those require amputation. Furthermore, developing increases the mortality by 50%–68% at 5 years, higher than some cancers. Current standard management includes surgical debridement, use topical dressings wound decompression, vascular assessment, glycemic control. Among these methods, local treatment builds protective physical barrier, maintains moist environment, drains exudate from wounds. This review summarizes development, pathophysiology, healing mechanisms The latest research progress main application in laboratory clinical stage are also summarized. discussed this include traditional (gauze, oil yarn, Chinese medicine, others), basic (hydrogel, hydrocolloid, sponge, foam, film agents, bacteriostatic dressings, composite (collagen, nanomaterials, chitosan bioactive (scaffold stem cells, decellularized matrix, autologous platelet enrichment plasma, modern technology (3D bioprinting, photothermal effects, bioelectric microneedle smart bandages, orthopedic prosthetics regenerative medicine). dressing challenges limitations purpose to help readers understand pathogenesis mechanism DFU, physicians select correctly, provide an updated overview potential biomaterials devices management, ideas for further exploration development dressings. Proper promote healing, reduce cost treating patient pain.

Language: Английский

---

How biomimetic nanofibers advance the realm of cutaneous wound management: The state-of-the-art and future prospects

Progress in Materials Science, Journal Year: 2024, Volume and Issue: 145, P. 101293 - 101293

Published: April 5, 2024

Language: Английский

---

The emergence of cancer sono-immunotherapy

Trends in Immunology, Journal Year: 2024, Volume and Issue: 45(7), P. 549 - 563

Published: June 23, 2024

Language: Английский

---

Advances in Radionuclide-Labeled Biological Carriers for Tumor Imaging and Treatment

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Biological carriers have emerged as significant tools to deliver radionuclides in nuclear medicine, providing a meaningful perspective for tumor imaging and treatment. Various radionuclide-labeled biological been developed meet the needs of biomedical applications. This review introduces principles radionuclide-mediated therapy selected criteria them, well comprehensive description characteristics functions representative including bacteria, cells, viruses, their derivatives, emphasizing labeled strategies combined with radionuclides. Subsequently, we in-depth introduce application treatment, behaviors vivo metastasis treatment by radionuclide therapy, plus other radiation-induced photodynamic therapy. Finally, challenges prospects are discussed improve shortcomings this innovative platform promote clinical transformation field medical imaging.

Language: Английский

---

A Membrane‐Targeted Photosensitizer Prevents Drug Resistance and Induces Immune Response in Treating Candidiasis

Advanced Science, Journal Year: 2023, Volume and Issue: 10(35)

Published: Oct. 24, 2023

Abstract Candida albicans ( C. ), a ubiquitous polymorphic fungus in humans, causes different types of candidiasis, including oral candidiasis (OC) and vulvovaginal (VVC), which are physically mentally concerning financially costly. Thus, developing alternative antifungals that prevent drug resistance induce immunity to eliminate biofilms is crucial. Herein, novel membrane‐targeted aggregation‐induced emission (AIE) photosensitizer (PS), TBTCP‐QY, developed for highly efficient photodynamic therapy (PDT) candidiasis. TBTCP‐QY has high molar absorption coefficient an excellent ability generate 1 O 2 •OH, entering the interior due its permeability. Furthermore, can efficiently inhibit biofilm formation by suppressing expression genes related adhesion ALS3 , EAP1 HWP1 invasion SAP1 SAP2 MDR1 ) also advantageous eliminating potential fungal treat clinical infectious diseases. TBTCP‐QY‐mediated PDT targets OC VVC vivo mouse model, induces immune response, relieves inflammation, accelerates healing mucosal defects combat infections caused clinically isolated fluconazole‐resistant strains. Moreover, demonstrates biocompatibility, suggesting applications treatment VVC.

Language: Английский

---

Engineering Clinically Relevant Probiotics with Switchable “Nano‐Promoter” and “Nano‐Effector” for Precision Tumor Therapy

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(5)

Published: Oct. 4, 2023

Probiotics have the potential as biotherapeutic agents for cancer management in preclinical models and human trials by secreting antineoplastic or immunoregulatory tumor microenvironment (TME). However, current probiotics lack ability to dynamically respond unique TME characteristics, leading limited therapeutic accuracy efficacy. Although progress has been made customizing controllable through synthetic biology, engineering process is complex predictability of production relatively low. To address this, here, first time, this work adopts pH-dependent peroxidase-like (POD-like) artificial enzymes both an inducible "nano-promoter" "nano-effector" engineer clinically relevant achieve switchable control probiotic therapy. The nanozyme initially serves "nano-promoter," generating trace amounts nonlethal reactive oxygen species (ROS) stress upregulate acidic metabolites probiotics. Once acidify a threshold, switches "nano-effector," producing great deal lethal ROS fight cancer. This approach shows promise subcutaneous, orthotopic, colitis-associated colorectal tumors, offering new methodology modulating metabolism pathological environment.

Language: Английский

---

Bio-Hybrid Magnetic Robots: From Bioengineering to Targeted Therapy

Bioengineering, Journal Year: 2024, Volume and Issue: 11(4), P. 311 - 311

Published: March 26, 2024

Magnetic robots possess an innate ability to navigate through hard-to-reach cavities in the human body, making them promising tools for diagnosing and treating diseases minimally invasively. Despite significant advances, development of with desirable locomotion full biocompatibility under harsh physiological conditions remains challenging, which put forward new requirements magnetic robots’ design material synthesis. Compared that are synthesized inorganic materials, natural organisms like cells, bacteria or other microalgae exhibit ideal properties vivo applications, such as biocompatibility, deformability, auto-fluorescence, self-propulsion, well easy functional therapeutics engineering. In process, these can provide autonomous propulsion biological fluids external fields, while retaining their functionalities integrating artificial robots, thus aiding targeted therapeutic delivery. This kind robotics is named bio-hybrid robotics, this mini-review, recent progress including design, engineering potential delivery will be discussed. Additionally, historical context prominent examples introduced, complexities, pitfalls, opportunities associated

Language: Английский

---

NIR‐II‐Responsive Hybrid System Achieves Cascade‐Augmented Antitumor Immunity via Genetic Engineering of Both Bacteria and Tumor Cells

Advanced Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 26, 2024

Abstract The combination of nanoparticles and tumor‐targeting bacteria for cancer immunotherapy can overcome the shortcomings poor nanoparticle accumulation, limited penetration, restricted distribution. However, it remains a great challenge hybrid system to improve therapeutic efficacy through simultaneous controllable regulation immune cells tumor cells. Herein, platform is rationally designed achieve cascade‐augmented immunotherapy. To construct hybrids, photothermal responsive light in second near‐infrared (NIR‐II) region are conjugated onto surface engineered pH‐responsive Schiff base bonds. Taking advantage hypoxia targeting deep penetration characteristics bacteria, hybrids accumulate at sites. Then detach from realize genetic engineering cells, which induces cell apoptosis down‐regulate expression programmed death ligand 1 alleviate immunosuppressive microenvironment. mild heating not only induce tumor‐associated antigen release, but also trigger sustainable cytokine interleukin‐2. Notably, synergistic antitumor effect achieved between process p53 transfection NIR‐II light‐activated bacteria. This work proposes facile strategy construction

Language: Английский

---

Harnessing Akkermansia muciniphila for astaxanthin delivery: A promising strategy for alleviating inflammatory bowel diseases

Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 106023 - 106023

Published: Feb. 1, 2025

Language: Английский

---

Advanced Disease Therapeutics Using Engineered Living Drug Delivery Systems

Nanoscale, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Biological barriers significantly impede the delivery of nanotherapeutics to diseased tissues, diminishing therapeutic efficacy across pathologies such as cancer and inflammatory disorders. Although conventional strategies integrate multifunctional designs molecular components into nanomaterials (NMs), many approaches remain insufficient overcome these barriers. Key challenges, including inadequate drug accumulation at target sites nonspecific biodistribution, persist in nanotherapeutic development. NMs, which harness ability precisely modulate spatiotemporally control release kinetics, represent a transformative platform for targeted therapy. In this review, we highlight biological obstacles limiting effective treatment evaluate how stimuli-responsive NMs address constraints. By leveraging exogenous endogenous stimuli, improve specificity, reduce off-target effects, amplify activity within pathological microenvironments. We systematically analyze rational design synthesis driven by advances oncology, biomaterials science, nanoscale engineering. Furthermore, NM classes-including polymeric, lipid-based, inorganic, hybrid systems explore functionalization using targeting ligands, antibodies, biomimetic coatings. Diverse are evaluated, small-molecule prodrug activation, peptide- protein-based targeting, nucleic acid payloads, engineered cell-mediated transport. Despite promise challenges biocompatibility, scalable fabrication, clinical translation must be addressed. elucidating structure-function relationships refining stimulus-triggered mechanisms, pave way precision oncology strategies, enabling patient-specific therapies with enhanced safety. This interdisciplinary insights aims catalyze innovation next-generation nanomedicine treatment.

Language: Английский

---